Menu

You must be logged in to take this course  →   LOGIN | REGISTER NOW

Highlights of the SAMHSA TIP 63- Medications for Opioid Use Disorder- A Toolkit for Improving Practice

This module is intended to address the opioid-specific education requirements under Maine Public Law Chapter 488. At the end of this module, users should understand Substance Abuse and Mental Health Services Administration (SAMHSA) Tip 63 which details the three FDA approved medications used to treat Opioid Use Disorder (OUD) and Substance Use Disorder (SUD).

115 STUDENTS ENROLLED

Learning Objectives:

  • Understand SAMHSAs goals, purpose for developing TIP63, Medications for OUD
  • Describe general principles, approach to use of medications for OUD
  • Understand indications, goals, key treatment principles for using methadone for OUD treatment
  • Understand indications, goals, key treatment principles for using buprenorphine for OUD treatment, including newer formulations
  • Understand indications, goals, key treatment principles for using naltrexone for OUD treatment
  • Describe principles of medical management for Office Based OUD Treatment (OBOT)
  • Describe key ways in which TIP63 challenges many traditional beliefs about how to manage patients with OUD

Module Structure:

This module is self-paced and available to any user that registers with the QC Learning Lab. The estimated time to complete is approximately 90 minutes. This module will be eligible to grant 1.5 AMA PRA Category 1 Continuing Medical Education (CME) Credits.

The module will consist of multiple sub-sections or units and will contain various elements, including hyperlinks to readings and web resources, video lessons, an evaluation survey and pre- and post-assessments needed to receive the CME credits.

Duration & Fee:

  • Estimated Time to Complete: 1.5 hours

(note: the module is divided into short digestible units [10-20 mins] which can be completed in small increments)

  • Registration Fee: FREE for Maine Clinicians
  • CME Credits Offered: 1.5

Hardware/Software Requirements:

  • Computer with Internet connection
  • Current version of Chrome, Firefox or Safari browser. You must have javascript enabled.
  • The quiz tool within the online modules are not fully compatible with smartphones or tablets. In order to avoid issues, such as answers not being recorded, we recommend using a computer to complete the pre- and post-tests.

Assessment and Grading:

This learning module begins with a pre-test that will test your knowledge and allow you to gauge your baseline understanding of the topics to be covered. Your pre-test score will not count toward your overall grade. At the end of the module, there is a post-test that will determine your final grade. A comparison of your pre-test score and post-test score will help to assess how much knowledge you’ve gained. You will have three attempts to complete the post-test. Your score must be 75% or better in order to receive a certificate for CME credit. Please complete the evaluation survey at the conclusion of the learning module.

This activity qualifies for 1.5 CME credits of the 3 CME credit requirement for opioid medication education found in P.L. 2015, Chapter 488, Maine’s recent legislation to address the opioid drug abuse crisis.

To Obtain CME Credits:

  • Complete the entire learning module.
  • Complete the pre-test, post test, and Evaluation Survey at the end of the module.
  • You must earn a score of 75% or higher on the post-test in order to qualify for CME credits. You will have three attempts to complete the post-test.
  • The official CME Documentation Form will be available to download from within the evaluation survey, after you answer all the questions and enter in your contact information. A generic certificate of completion is available upon request.

Table of Contents:

  • Introduction
  • Pre-Assessment
  • Part 1 – Purpose and Development of TIP 63- An Introduction to Medications for the Treatment of Opioid Use Disorder
  • Part 2- Addressing Opioid Use Disorders in General Medical Settings
  • Part 3 Chapter 3B  – Methadone
  • Part 3 Chapter 3D – Buprenorphine
  • Part 3 Chapter 3C – Naltrexone
  • Part 3 Chapter 3E – Medical Management Strategies for Patients Taking OUD Medications in Office Based Settings
  • Module Resources
  • Post-Assessment
  • Evaluation Survey

Disclosures: 

Michelle Lofwall, MD, DFASAM
Associate Professor in the Departments of Behavioral Science and Psychiatry
Medical Director of the Robert Straus Clinic and the First Bridge Clinic

Lisa Letourneau, MD
Acting Medical Director
Qualidigm

Kayla Cole, CSM, CSP
Project Manager
Qualidigm

Pieter Tryzelaar, M.Ed, MFA (Course Developer)
Manager of Education and Learning
Qualidigm

TAKE THIS COURSE
  • FREE
  • UNLIMITED ACCESS
  • Course Badge
top
 Copyright 2019